Nature and extent of the burden and risks: In the experimental arm, the risk of this study primarily consists of treatment-related toxicity and morbidity of combination chemotherapy and bevacizumab, which should be weighed against potential survival benefit. Furthermore, some patients in the experimental arm may have disease progression upon neoadjuvant treatment to an extent that does not allow CRS + HIPEC. However, it is highly questionable whether these patients would have derived a benefit from upfront CRS + HIPEC at all, and the investigators hypothesise that a neoadjuvant treatment strategy allows for better patient selection and spares the morbidity of this intervention to patients who are unlikely to benefit.